Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

NCT06433219 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

63

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: Tuvusertib (M1774)
DRUG: Niraparib
DRUG: Lartesertib (M4076)

Sponsor

EMD Serono Research & Development Institute, Inc.

Collaborators

[object Object]